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Abstract
Background: Dendritic cells (DCs) not only play a crucial role in activating immune cells but also suppressing them. We
recently investigated SHIP’s role in murine DCs in terms of immune cell activation and found that TLR agonist-stimulated
SHIP2/2 GM-CSF-derived DCs (GM-DCs) were far less capable than wild type (WT, SHIP+/+) GM-DCs at activating T cell
proliferation. This was most likely because SHIP2/2 GM-DCs could not up-regulate MHCII and/or co-stimulatory receptors
following TLR stimulation. However, the role of SHIP in DC-induced T cell suppression was not investigated.
Methodology/Principal Findings: In this study we examined SHIP’s role in DC-induced T cell suppression by co-culturing
WT and SHIP2/2 murine DCs, derived under different conditions or isolated from spleens, with aCD3+ aCD28 activated WT
T cells and determined the relative suppressive abilities of the different DC subsets. We found that, in contrast to SHIP+/+
and 2/2 splenic or Flt3L-derived DCs, which do not suppress T cell proliferation in vitro, both SHIP+/+ and 2/2 GM-DCs
were capable of potently suppressing T cell proliferation. However, WT GM-DC suppression appeared to be mediated, at
least in part, by nitric oxide (NO) production while SHIP2/2 GM-DCs expressed high levels of arginase 1 and did not
produce NO. Following exhaustive studies to ascertain the mechanism of SHIP2/2 DC-mediated suppression, we could
conclude that cell-cell contact was required and the mechanism may be related to their relative immaturity, compared to
SHIP+/+ GM-DCs.
Conclusions: These findings suggest that although both SHIP+/+ and 2/2 GM-DCs suppress T cell proliferation, the
mechanism(s) employed are different. WT GM-DCs suppress, at least in part, via IFNc-induced NO production while SHIP2/2
GM-DCs do not produce NO and suppression can only be alleviated when contact is prevented.
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Introduction
Dendriticcells(DCs)havelongbeenrecognizedasactivatorsofthe
immune system [1–3] and, more recently, as critical players in the
induction of central tolerance [4] as well as the induction and
maintenance of peripheral tolerance [5]. Several signals are involved
in determining the nature of the interaction between T cells and DCs,
including the antigen (Ag)-specific interaction between the T cell
receptor (TCR) on T cells and the peptide-bound major histocom-
patibility complex molecule on DCs, contact mediated signals
transduced by co-stimulatory or tolerogenic receptors and secreted
cytokines [6]. Under normal steady state conditions, DCs maintain
tolerance by either inducing Tregs [7] or by causing deletion or
anergy of self-reactive T cells [8]. DCs with these suppressive
properties can be generated in vitro and have many potential
applications, such as in the treatment of autoimmune disorders or
organ transplants. A greater understanding of the mechanisms
involved will allow tailoring of DCs for specific applications.
Currently very little is known about the mechanisms that DCs
employ to suppress T cell proliferation. In one report, DCs derived
from rat bone marrow (BM) using granulocyte macrophage colony
stimulating factor (GM-CSF) 6 interleukin (IL)-4 were shown to
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21893have an intrinsic ability to prevent T cell proliferation while those
derived using fms-like tyrosine kinase ligand (Flt3L) did not [9].
However, the specific mechanism of DC-mediated suppression
was not determined in this study. In another study, using myeloid
dendritic cell (mDC) precursors, isolated as CD11c
2 cells from
GM-CSF cultures, these cells were shown to suppress T cell
proliferation via a contact-dependent, NO-mediated mechanism
[10]. In addition, DCs that were exposed to tumor cells were
found to become immunosuppressive by down-regulating the
TCR component CD3e on T cells, and by inducing reactive
oxygen species (ROS)-mediated T cell apoptosis [11]. Taken
together, these data illustrate a diversity of mechanisms available
to DCs to induce T cell suppression. Importantly, the environment
in which the DCs are generated appears to influence both their
ability to suppress and the suppressive mechanism they employ.
Interestingly, immune suppression is not a function associated
only with DCs. Several cell types including regulatory T cells
(Tregs) [12] and tumor-induced myeloid-derived suppressor cells
(MDSCs), which are characterized by the co-expression of Gr1
and CD11b [13], are capable of immune suppression. The
mechanisms of suppression used by these cells are quite diverse.
Suppression by Tregs, for example, is often associated with either
membrane bound- or secreted TGFb-induced anergy [14],
cytokine deprivation-mediated apoptosis [15] and/or contact-
dependent cell death, involving granzyme B [16]. MDSCs, on the
other hand, often use a different arsenal of suppressive
mechanisms, including arginase 1 (Arg 1) [17]. Related to this,
the amino acid, L-arginine, can be metabolized by inducible nitric
oxide synthase (iNOS, also known as NOS2), into nitric oxide
(NO), or it can be converted into L-ornithine by the enzyme Arg 1
[18]. Co-expression of these two enzymes can lead to the
generation of reactive nitrogen-oxide species (RNOS) such as
peroxynitrite which, in turn, nitrosylates the TCR and other
proteins, causing T cell suppression [19].
The SH2-containing inositol 59 phosphatase (SHIP) is a critical
negative regulator of the phosphoinositol 3-kinase (PI3K) pathway
with known functions in regulating myeloid cell development and
survival [20]. Recently, we showed that SHIP-deficient DCs,
generated in the presence of GM-CSF, were less mature than wild
type (WT, SHIP+/+) DCs and were far less able to up-regulate
MHCII and co-stimulatory receptors in response to Toll like
receptor (TLR) activation than WT GM-CSF derived DCs (GM-
DCs) and this resulted in these SHIP2/2 GM-DCs being far less
able to induce Ag-specific T cellproliferation[21]. However, we did
not look at SHIP’s role in the suppressive ability of various DC
subsets. In this study, we were interested in determining if the
inability of SHIP2/2 DCs to activate T cells translated into an
enhanced suppressive ability. Specifically, we compared the ability
of SHIP +/+ and 2/2 DCs derived with GM-CSF, Flt3L (FL-
DCs) or isolated from spleens to suppress polyclonally activated T
cells in order to ascertain the role of SHIP in DC-induced T cell
suppression. Our results reveal that naı ¨ve WT and SHIP-deficient
GM-DCs suppress T cell proliferation to the same extent while
SHIP+/+ and 2/2 Flt3L-derived or splenic DCs do not suppress
at all. Moreover, we discovered that SHIP2/2 GM-DCs express
Arg 1 and do not produce NO, while WT GM-DCs do not express
Arg 1 and suppress T cell proliferation, in part, via NO-production.
Results
WT and SHIP2/2 GM-CSF-derived DCs are equally
suppressive
To test whether WT or SHIP2/2 DCs isolated from the spleen
or derived under different culture conditions had suppressive
activity, we cultured different cell concentrations of these DCs with
splenic T cells activated with aCD3+ aCD28. As shown in Fig 1A,
SHIP+/+ and 2/2 DCs isolated from the spleen or derived using
Flt3L did not suppress T cell proliferation at any DC dose tested.
In contrast, SHIP+/+ and 2/2 GM-DCs suppressed T cell
proliferation in a similar, cell dose dependent manner, with greater
than 50% suppression achieved with the addition of 12.5610
3
DCs to 2610
5 WT splenocytes (Fig 1A). Unlike our previous study
in which we found that SHIP2/2 GM-DCs were far less capable
than WT GM-DCs at activating T cell proliferation [21], these
results show that SHIP+/+ and 2/2 GM-DCs are equally potent
at suppressing T cell proliferation.
In addition to T cell proliferation, we also analyzed cytokine
secretion from aCD3+ aCD28 stimulated WT spleen cells co-
cultured with SHIP+/+ or 2/2 DCs and found that the
production of the T cell cytokines IFNc, IL-10, IL-17 and IL-13
correlated with our T cell proliferation results, ie, when
activated T cells were co-cultured with either splenic DCs or
FL-DCs there was no reduction in IFNc, IL-10, IL-17 or IL-13
(Fig 1B and C) but when aCD3+ aCD28 stimulated WT spleen
cells were co-cultured with SHIP+/+ or 2/2 GM-DCs, the
levels of these cytokines were significantly reduced (Fig 1D). In
addition to cytokines, we also determined the NO levels
produced in the co-cultures and found the addition of
SHIP+/+ GM-DCs significantly increased NO levels. Interest-
ingly, however, addition of SHIP2/2 GM-DCs resulted in very
little NO production (Fig 1D, far right panel). Importantly,
when activated T cells were co-cultured with either splenic DCs
or FL-DCs there was very little NO secreted (Fig 1B and C, far
right panel).
WT GM-DCs suppress, in part, by an NO-dependent
mechanism
Since WT CD11c
2 mDC precursors have been shown to
prevent T cell proliferation via an NO-mediated mechanism [10],
we investigated whether NO was involved in the suppression
mediated by SHIP+/+ or 2/2 GM-DCs. Specifically, we asked if
an NO scavenger, carboxy PTIO, or an iNOS inhibitor, L-
NMMA, could ameliorate the T cell suppression induced by these
GM-DCs. As can be seen in Fig 2A (left panel), the addition of
carboxy PTIO significantly reduced the level of WT GM-DC-
induced suppression, as did the addition of L-NMMA in a dose
dependent manner. A combination of the two caused a dramatic
reduction. These inhibitors, however, had no effect on the ability
of SHIP2/2 GM-DCs to suppress WT T cell proliferation
(Fig 2A), consistent with their inability to produce NO in co-
cultures (Fig 1B). The reduction in WT GM-DC-induced
suppression via carboxy PTIO also correlated with a reduction
in NO production while L-NMMA prevented any detectable levels
of NO at all doses tested (Fig 2A, right panel). Worthy of note,
however, is that while L-NMMA, even at 0.5 mM, completely
eliminated NO secretion it only reduced T cell suppression by
approximately 25%, suggesting that a mechanism of suppression
other than NO was also being used by WT GM-DCs. Since NO-
dependent mechanisms employed to suppress T cell proliferation
have been reported to often involve IFNc, which is secreted by
activated T cells and induces iNOS expression in macrophages
and DCs [10,22–25] we tested the effect of a neutralizing Ab to
IFNc and found that SHIP+/+ GM-DCs were significantly less
capable of suppressing T cell proliferation in the presence of this
Ab and that less NO was generated in these co-cultures (Fig 2B).
No effect was observed in SHIP2/2 cultures, consistent with the
inability of SHIP2/2 DCs to induce NO.
SHIP-/- DCs Suppress T Cells but Not via NO
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mediated by amino acid depletion
The expression of Arg 1 in macrophages and MDSCs has been
shown to be one mechanism by which these cells suppress T cell
proliferation and this enzyme suppresses via sequestering L-
arginine away from iNOS and converting it into L-ornithine
instead of NO [13,17,18]. Related to this, SHIP2/2 peritoneal
macrophages have been shown to have an alternatively activated,
immunosuppressive M2 phenotype, characterized by high Arg 1
expression and this has been linked to enhanced tumor growth in
SHIP-deficient mice [26]. In addition, we have found that GM-
CSF- and IL-3-derived SHIP2/2 macrophages express high
levels of Arg1 as a result of basophil produced IL-4 [27]. We
therefore examined the expression of Arg 1 in SHIP+/+ and 2/2
DCs derived under different culture conditions (Fig 3A). We found
that SHIP2/2 DCs derived in the presence of GM-CSF
expressed Arg 1, likely as a result of SHIP2/2 basophil produced
IL-4 [27], while WT GM-DCs did not. In contrast, neither
Figure 1. SHIP+/+ and 2/2 GM-DCs suppress T cell activation. 2610
5 WT splenocytes were stimulated with soluble aCD3+ aCD28
antibodies and incubated with the indicated number of SHIP+/+ or 2/2 A) CD11c
+ splenic DCs, FL- or GM-DCs. Proliferation was determined
after 72 hrs by incorporation of
3H - t h y m i d i n ef o rt h el a s t1 8h r s .D a t as h o w na r et h em e a n6 SEM of triplicate cultures and are representative
of more than 3 independent experiments. Supernatants were collected after 72 hrs from B) Splenic (25610
3) C) Flt3L-derived (25610
3)a n d
D) GM-derived DCs (50610
3) co-cultures and subjected to cytokine ELISAs or Griess assays for NO determination. Data shown are the mean 6
SEM of triplicate cultures and are representative of 2–3 independent experiments. *p,0.05 relative to stimulated splenocytes in the absence
of DCs (Ctrl).
doi:10.1371/journal.pone.0021893.g001
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(Fig 3A). We also looked at Arg 1, Arg 2 and Nos2 (iNOS) mRNA
levels in naive SHIP+/+ and 2/2 GM-DCs and FL-DCs by
qPCR. We found increased expression of Arg 1 and iNOS in
SHIP2/2 GM-DCs compared to SHIP+/+ GM-DCs while both
SHIP+/+ and 2/2 FL-DCs expressed very low levels of Arg 1 and
iNOS (Fig 3B). While it is interesting that SHIP2/2 GM-DCs
express higher iNOS levels than WT GM-DCs, at least at the
mRNA level in naive DCs, the fact that SHIP2/2 GM-DCs also
express very high levels of Arg 1 likely prevents them from
producing significant amounts of NO. Also of interest, no
significant differences were detected in mRNA levels of Arg 2
between SHIP+/+ or 2/2 GM or FL-DCs (Fig 3B).
Since suppression of T cell proliferation can be achieved through
the expression of Arg 1 and subsequent depletion of L-arginine [28]
we asked if SHIP2/2 GM-DCs were suppressing T cell
proliferation via this mechanism by using the Arg 1 inhibitor,
BEC ([S]-[2-boronoethyl]-L-cysteine-HCl). However, we found
that there was no reversal of suppression in either the SHIP+/+ or
2/2DCco-cultures(Fig 3C). Wealsoadded exogenous L-arginine
to cultures and found no reversal of suppression. The amino acid
tryptophan, which is the rarest essential amino acid and thus may
cause a ‘‘bottle-neck’’ in protein synthesis, has also been reported,
upon local depletion, to cause T cell anergy and death [29,30].
Related to this, indoleamine 2,3-dioxygenase (IDO, or Indo), a key
tryptophan-degrading enzyme, is expressed by some DC subsets
[29] and generates tryptophan catabolites that can lead to T cell
apoptosis [31]. We therefore determined the expression of Indo, and
found that it was expressed at very low levels in SHIP+/+ and 2/2
GM-DCs and FL-DCs, with SHIP+/+ GM-DCs having the highest
expression (Fig 3B, far right panel). To test if IDO played a role in
either SHIP+/+ or 2/2 GM-DC-induced T cell proliferation we
added an IDO inhibitor, exiguamine A [32], to co-cultures but
found that inhibiting IDO had no effect, nor did the addition of
exogenous L-tryptophan (Fig 3C).
Neither SHIP+/+ nor 2/2 GM-DCs suppress T cell
proliferation via secreted immunosuppressive cytokines
Apart from depleting amino acids in the local milieu, T cell
suppression is often mediated by local secretion of immunosup-
pressive cytokines. Therefore, we neutralized several cytokines
with known or potential suppressive functions. However, addition
of neutralizing antibodies to IL-4, IL-13, IL-6, IL-10 and TGFb,
resulted in no amelioration of T cell suppression induced by either
SHIP+/+ or 2/2 GM-DCs (Fig 4A). As well, since TGFb is often
membrane bound and expressed at the cell surface in a latent form
via its non-covalent association with latency associated peptide
(LAP) [33], we added exogenous LAP to retain TGFb in an
inactive state. This too had no effect on the level of T cell
suppression (Fig 4A). These results suggest that the DC secreted
cytokines, IL-4, IL-13, IL-6, IL-10 and TGFb, or membrane-
bound TGFb, are not responsible for the T cell suppression
induced by SHIP+/+ or 2/2 GM-DCs.
IL-2 is an important autocrine-acting cytokine that T cells
produce to promote their own proliferation [34]. We therefore
asked if the suppression of T cell proliferation induced by SHIP+/+
or SHIP2/2 GM-DCs was occurring via inhibition of IL-2
production. To test this, we added exogenous IL-2 to co-cultures of
aCD3+ aCD28 stimulated WT splenocytes with SHIP+/+ or2/2
GM-DCs and found that this enhanced T cell proliferation in the
Figure 2. SHIP+/+ but not 2/2 GM- DC-induced T cell suppression is mediated by IFNc-dependent NO production. WT splenocytes
were stimulated with soluble aCD3+ aCD28 Abs and incubated with SHIP+/+ or 2/2 GM-DCs (50610
3) for 72 hrs. A) Left panel, relative percent
suppression of proliferation in the absence (ctrl) or presence of 25 mg/ml PTIO, 0.5 mM–2.5 mM L-NMMA or 25 mg/ml PTIO +0.5 mM L-NMMA). Right
panel, NO production using the same concentrations of PTIO and/or L-NMMA. B) WT splenocytes were stimulated with soluble aCD3+ aCD28 Abs
and incubated with SHIP+/+ or 2/2 GM-DCs (50610
3) 610 mg/ml neutralizing aIFNc. Left panel, percent suppression of T cell proliferation. Right
panel, NO production. Data shown are mean 6 SEM of triplicate cultures and are representative of 3 independent experiments. *p,0.05 relative to
genotype control, ns = not significantly different. . indicates level is below detection.
doi:10.1371/journal.pone.0021893.g002
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present (Fig 4B). We also tested whether SHIP+/+ or 2/2 GM-
DCs were reducing IL-2R expression on the T cells. However, the
expression of CD25 (the IL-2Ra) on CD4
+ T cells was increased
compared to controls when either SHIP+/+ or 2/2 GM-DCs
were present (Fig 4C). Therefore, neither SHIP+/+ nor 2/2 GM-
DCs were reducing the ability of WT splenic T cells to use IL-2 via
down-regulation of its receptor.
SHIP+/+ and 2/2 GM-DCs suppress via a contact-
dependent mechanism
T cell suppression can be mediated by soluble cytokines, by
direct cell-cell contact, or both [35]. To determine if suppression
was contact dependent, since it did not appear to be mediated by
known immunosuppressive cytokines, we carried out transwell
studies. As shown in Fig 5A, separation of aCD3+ aCD28-
activated T cells from SHIP+/+ or 2/2 GM-DCs by a semi-
permeable membrane abrogated suppression at all cell doses
tested. This is in agreement with WT GM-DCs suppressing via an
NO-dependent mechanism, since although not necessarily requir-
ing direct cell contact, close proximity is required because of the
short half-life (5 seconds) of NO. Reactive oxygen species (ROS)
have also been implicated in phagocyte-induced T cell suppression
[36], and like NO, require close proximity to exert their effects. To
determine if ROS were involved in either SHIP+/+ or 2/2 GM-
DC-induced T cell suppression, we added the ROS scavengers N-
acetyl-cysteine (NAC), catalase or superoxide dismutase (SOD) to
activated T cell cultures containing either SHIP+/+ or 2/2 GM-
Figure 3. SHIP2/2 GM-DCs express Arg 1. A)F Day 8 SHIP+/+ and 2/2 GM- and FL-DCs were subjected to Western analysis using Abs to SHIP,
Arg1 and Grb2 as a loading control. Data shown are representative of at least 3 independent experiments. B) mRNA expression of Arg 1, Arg 2, Nos2,
and Indo in SHIP+/+ and SHIP2/2 GM- and FL-DCs. Data shown is mean 6 SEM of duplicate determinations from 2–3 independent experiments.
*p,0.05 relative to SHIP+/+. C) WT splenocytes were stimulated with soluble aCD3+ aCD28 Abs and incubated with SHIP+/+ or 2/2 GM-DCs
(50610
3) 6100 mM of the arginase inhibitor, Bec, 2 mM L-arginine (L-Arg), 1 mM of the IDO inhibitor, exiguamine A (Exi) or 200 mM L-tryptophan (L-
Tryp). Data shown are the mean 6 SEM of triplicate determinations and are representative of 2 independent experiments.
doi:10.1371/journal.pone.0021893.g003
Figure 4. Secreted cytokines are not responsible for T cell suppression. A) WT splenocytes (2610
5) were stimulated with soluble aCD3+
aCD28 Abs and co-incubated with SHIP+/+ or 2/2 GM-DCs (50610
3) containing isotype control Ab (iso) or the indicated neutralizing cytokine Ab
(10 mg/ml) or LAP (250 ng/ml). B) WT splenocytes were stimulated with soluble aCD3+ aCD28 Abs and incubated with the indicated number of
SHIP+/+ and 2/2 GM-DCs and IL-2 (100 U) was added as indicated and proliferation determined after 72 hrs. Data shown are the mean 6 SEM of
triplicate cultures and is representative of at least 2 independent experiments. C) CD4
+ T cells from SHIP+/+ and 2/2 GM-DC (50610
3) co-cultures
were analyzed for expression of CD25 by flow cytometry. Splenocyte control = grey fill, WT GM-DCs = black line and SHIP2/2 GM-DCs = grey line.
Data shown are representative of 2 independent experiments.
doi:10.1371/journal.pone.0021893.g004
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scavengers had no effect on T cell proliferation. These results
demonstrate that although the mechanism of suppression requires
close proximity, it is not ROS dependent.
To determine if specific contact molecules on the surface of
SHIP+/+ or 2/2 GM-DCs were responsible for T cell
suppression, we blocked the inhibitory receptor CTLA-4 or the
adhesion molecules, LFA-1+ Mac-1 (CD11b), with neutralizing
Abs. Under both conditions no change in the level of suppression
was detected (Fig 5B, right panel). Also, since it was recently
reported [37] that alternatively activated, M2 macrophages
express programmed death ligand 2 (PD-L2) and that blockade
of PD-L2 prevented M2-macrophage-induced suppression of T
cells we asked if SHIP+/+ or 2/2 GM-DCs (which exhibit
several hallmarks of M2 macrophages) were using PD-L2 to
mediate their contact-dependent suppression of T cell prolifera-
tion. However, neither SHIP+/+ or SHIP2/2 GM-DC-induced
suppression was reversed with a blocking Ab to PD-L2 (Fig 5B,
right panel).
Wealsotestedifsuppressioncouldbeoccurringindirectlythrough
the induction of Tregs. Treg induction can occur both through
contact-dependent and -independent mechanisms [14,38,39]. How-
ever, SHIP2/2 GM-DCs induced fewer Tregs when co-cultured
with conventional WT T cells (ie, CD4
+CD25
2CD45RB
hi)s u g -
gesting, at least, that this is likely not the mechanism of suppression
employed by SHIP2/2 GM-DCs (Fig 5C).
Discussion
In this study we compared the ability of SHIP+/+ and 2/2
splenic, Flt3L and GM-CSF-derived DCs to suppress polyclonal T
cell proliferation and found that both SHIP+/+ and SHIP2/2
GM-DCs have an intrinsic ability to suppress T cell proliferation
while splenic and FL-DCs do not. Upon further investigation of
the mechanism of suppression employed by these GM-DCs, we
discovered that SHIP+/+ GM-DCs use, in part, a close proximity-
dependent, IFNc-induced NO production mechanism, possibly in
concert with induced Tregs (see Model, Fig 6). SHIP2/2 GM-
DCs, on the other hand, do not produce significant amounts of
NO, likely because of high Arg 1 expression, and their suppression
of aCD3+ aCD28-induced T cell proliferation cannot be reversed
through IFNc neutralization or inhibition of iNOS.
A number of studies have been conducted to investigate the
influence of DC culture conditions on the ability of the derived
DCs to suppress T cell activation in vitro. Based on these studies,
the dose of GM-CSF as well as the presence or absence of IL-4
used in culture was found to impact the resultant phenotype [40].
Specifically, DCs derived from BM with low GM-CSF concen-
trations were found to be phenotypically immature and induced
T cell unresponsiveness. In addition, these cells were much more
resistant to LPS, TNFa and CD40-induced maturation, but were
sensitive to the effect of IL-4-induced maturation. On the other
hand, DCs derived with high doses of GM-CSF were more
mature and showed little phenotype/functional difference with
the addition of IL-4 [40]. These studies [40,41] did not elucidate
a mechanism of action of T cell unresponsiveness beyond the
suggestion that the immature phenotype prevented activation. In
our current studies, DCs were cultured in the presence of high
doses (10 ng/ml) of GM-CSF. Rossner et al, on the other hand,
found that the non-DC fraction (CD11c
2) of 8–10 day low GM-
CSF cultures and 3–4 day high GM-CSF cultures suppressed T
cell activation via a contact and NO-dependent mechanism [10].
Figure 5. SHIP+/+ and 2/2 GM-CSF-derived DCs suppress via a contact-dependent mechanism. A) The indicated number of SHIP+/+ and
2/2 GM-DCs were plated in the bottom chamber of a 0.4 mm 96 well transwell plate and WT splenocytes (2610
5 ) were stimulated with soluble
aCD3+ aCD28 Abs and plated in the top chamber. Proliferation was determined after 72 hrs by incorporation of
3H-thymidine for the last 18 hrs. Data
shown are the mean 6 SEM of triplicate cultures and are representative of 3 independent experiments. B) Left panel, relative percent suppression
with the addition of agents that reduce the presence of ROS (2 mM NAC, 100 U/ml catalase, 200 U/ml SOD). Right panel, relative percent suppression
with the addition of blocking antibodies to CTLA4 (10 mg/ml), LFA1+ mac1 (5 mg/ml each) and PD-L2 (10 mg/ml). Data shown are the mean 6 SEM of
triplicate cultures and are representative of at least 2 independent experiments with the exception of PD-L2 which was only performed once. C)
SHIP+/+ and 2/2 GM-DCs were cultured for 4 days with WT sorted conventional T cells at a ratio of 1:2 DCs to T cells and analyzed for Treg induction
by flow cytometry. Data shown are the mean 6 SEM of two independent experiments.
doi:10.1371/journal.pone.0021893.g005
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results are similar to those we obtained with our SHIP+/+
CD11c
+ day 8, high concentration GM-CSF cultures. Consistent
with our results, it has been reported that rat BM-derived DCs,
but not splenic DCs produce NO and are capable of T cell
suppression [42]. As well, like us, Taieb et al found that rat Flt3-
derived DCs could not suppress T cell proliferation [9].
Unfortunately, as already mentioned, many factors can influence
the DCs generated, including not only GM-CSF concentration
but the age of the mice used, starting cell density, mechanical
stress and batch to batch variation in fetal calf serum [43]. This,
together with the finding that DCs may differ somewhat if
derived with recombinant GM-CSF versus GM-CSF from
conditioned media, makes literature comparisons difficult. In
addition, the way in which T cells are activated also appears to
influence the ability of myeloid cells to suppress, at least in the
case of MDSCs [22].
Intriguingly, our results demonstrate that DCs generated in the
presence of GM-CSF from SHIP2/2 BM are capable of
suppression, but that this suppression is not reversible by any
means tested, including those that reversed the suppressive activity
of SHIP+/+ GM-DCs. Not all mechanisms of suppression are
direct. A study using human DCs showed that regulatory DCs
induce CD4
+CD25
+ Tregs, which are capable of suppressing T
cell responses [44]. However, we found that SHIP2/2 GM-DCs
were less capable than WT GM-DCs at inducing Tregs, suggesting
this indirect mechanism is likely not responsible for SHIP2/2
GM-DC-induced T cell suppression. As well, given that one of the
primary mechanisms of Treg-induced suppression is via TGFb
[14], we found that neutralizing TGFb or adding LAP did not
affect the level of suppression of either SHIP+/+ or SHIP2/2
GM-DCs (Fig 4A), further suggesting Tregs are not likely a large
component of the suppressive mechanism.
In conclusion, we show that, unlike FL-DCs and splenic isolated
DCs, GM-CSF-derived WT and SHIP2/2 DCs are capable of
suppressing polyclonal T cell proliferation. It appears that WT
GM-DCs suppress, at least in part, via a contact and IFNc-
dependent induction of NO while SHIP2/2 DCs are incapable
of NO production and express high levels of the enzyme Arg 1, yet
are still equally suppressive, perhaps because of the immature
phenotype of these DCs [21]. Thus far, only prevention of contact
is able to reverse T cell suppression by SHIP2/2 GM-DCs which
suggests that they could be particularly good at preventing graft
versus host disease or prolonging allograft survival in mice because
of a reduced likelihood that they will be converted to immuno-
genic DCs in vivo. This finding could be applicable to a clinical
setting through the use of either inhibitors of SHIP or the use of
RNA interference to reduce SHIP levels in human BM-derived
DCs prior to transplant. Further understanding of the unique
mechanism of T cell suppression utilized by SHIP2/2 DCs will
likely reveal other targets for the pharmacological manipulation of
DC suppressive functions.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations set out by the Canadian Council on Animal
Care. The protocol was approved by the University of British
Columbia Animal Care Committee (protocol #A07-0503).
Figure 6. Model of SHIP+/+ and 2/2 GM-DC-induced T cell suppression. SHIP+/+ and 2/2 GM-DCs both suppress T cell proliferation in a
contact-dependent manner. aCD3+ aCD28-stimulated T cells secrete IFNc, which acts on WT GM-DCs to upregulate iNOS and secrete NO. This NO
then suppresses T cell proliferation. SHIP2/2 GM-DCs express Arg 1 and do not produce NO, but may use an alternate direct mechanism of
suppression or induce the expansion or differentiation of a regulatory cell, likely not Tregs, to suppress T cell proliferation. If a second cell type is
involved in SHIP2/2 GM-DC-induced suppression, its induction or activation is contact-dependent.
doi:10.1371/journal.pone.0021893.g006
SHIP-/- DCs Suppress T Cells but Not via NO
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e21893Mice
SHIP+/+ and 2/2 mice, backcrossed onto a C57Bl/6
background for at least 12 generations (provided by Dr Frank
Jirik, University of Calgary, Calgary, AB) were used between 6–12
weeks of age. Mice were maintained in the Animal Resource
Centre of the British Columbia Cancer Research Centre under
specific pathogen-free conditions.
Generation of GM-CSF-derived DCs
Red blood cell lysed bone marrow (BM) cells were cultured in
IMDM containing 10% FCS, 0.00125% (v/v) MTG, 2 mM
glutamine, 100 U/ml penicillin/streptomycin and 10 ng/ml
rmGM-CSF (GM-DCs). Cells were seeded at 6610
5 cells/well
(1 ml) in 12 well plates and 1 ml of fresh cytokine containing
medium was added on day 3. On days 5 and 7, half the cell-free
supernatant was replaced with fresh cytokine containing
medium. Non-adherent cells were harvested on day 8 and DCs
enriched by EasySepH CD11c-PE positive selection (StemCell
Technologies, Vancouver) according to the manufacturer’s
instructions.
Generation of Flt3L-derived DCs
Red blood cell lysed BM cells were cultured at 1.5610
6 cells/ml
in RPMI containing 10% FCS, 100 U/ml penicillin/streptomy-
cin, 50 mM b-ME and 100 ng/ml rmFlt3L. Cells were seeded at
4.5610
6 cells/well (3 ml/well) in 6 well plates and left for 8 days
after which non-adherent cells were harvested as Flt3L-derived
DCs (FL-DCs) and used in subsequent experiments.
Splenocyte preparation and splenic DC isolation
Spleens were harvested from WT mice and the cells extracted
by resuspending and passing through a 100 mm cell strainer. Red
blood cells were lysed with NH4Cl solution at a 1 volume cells: 3
volumes NH4Cl for 5–10 min on ice and the remaining cells
washed and resuspended in IMDM containing 10% FCS,
0.00125% (v/v) MTG, and 100 U/ml penicillin/streptomycin.
For splenic DC isolation, SHIP+/+ and 2/2 splenocytes were
washed and the DC population enriched using EasySepH CD11c-
PE positive selection (StemCell Technologies Inc.) according to the
manufacturer’s instructions.
Nitric oxide assay
NO production was determined indirectly by measuring the
accumulation of nitrite (NO2
2), a stable breakdown product of
NO, in the tissue culture supernatant using a modification of the
Griess assay [45,46]. Briefly, 50 ml of supernatant was sequentially
incubated with equal volumes of 1% sulfanilamide in 2.5%
phosphoric acid and 0.1% phenylnapthylenediamine dihydro-
chloride in 2.5% phosphoric acid at 23uC. After 5 min, the
absorbance of samples at 570 nm was determined and NO2
2
concentration calculated by comparison to a NaNO2 standard
curve.
T cell suppression assay
This assay was performed according to the protocol of
Thornton and Shevach [47] with a few modifications. SHIP+/
+ or 2/2 BMDCs or splenic DCs were plated at 5610
4 cells/
well in a 96 well flat bottom plate and serial 1:2 dilutions
performed down to 3.125610
3 cells/well. Prepared splenocytes
were stimulated with 0.5 mg/ml aCD3+2.5 mg/ml aCD28
(eBioscience, San Diego, CA) (to stimulate T cell proliferation)
and added (2610
5 cells/well) alone or to the DC-containing wells
in 200 ml total volume. Cells were incubated at 37uC for 72 hrs,
with
3H-thymidine (2 Ci/mmole, 1 mCi/well) added for the last
18 hrs. The contents of each well were then harvested onto
filtermats and counted using an LKB Betaplate Harvester and
Liquid Scintilation Counter (LKB Wallac, Turku, Finland).
Neutralizing Abs to IL-4 were from eBioscience (San Diego,
CA), to IL-10 and CTLA-4 from BD Biosciences (Mississauga,
ON, Canada), to IL-13, IFN-c, IL-6 and TGF-b from R&D
Systems (Minneapolis, MN). Catalase, N-acetyl-L-cysteine
(NAC), superoxide dismutase (SOD), and non-specific NOS
inhibitor N
G-monomethyl-L-arginine (L-NMMA) were from
Sigma-Aldrich (St. Louis, MO). Recombinant human latency-
associated peptide (LAP) was from R&D Systems and carboxy-2-
Phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO), an
NO scavenger, was from Cayman Chemicals (Ann Arbor, MI).
[(S)-(2-Boronoethyl)-L-cysteine] (BEC), a competitive inhibitor of
Arg1 and 2 that does not inhibit iNOS, was generously donated
by Dr J.-L.Boucher. (Universite Paris Descartes, Paris, France)
and exiguamine A by Dr. Ray Anderson (Vancouver, BC). TIB-
218, a rat IgG2ak Ab selective for the b subunit of mouse LFA-1
and CD11b (CD18) (aLFA-1+ MAC1), was purified from
hybridoma supernatants in house. Recombinant mouse IFN-c
and IL-2 were from StemCell Technologies (Vancouver, BC,
Canada). When used, these were added to DC-containing wells
just prior to the addition of the activated splenocytes. Percent
suppression of proliferation was calculated as follows:
1{
proliferation with DCs + inhibitor
proliferation without DCs + inhibitor

|100
Relative percent suppression of proliferation was calculated as
%Suppression with inhibitor
%Suppression without inhibitor
|100
In parallel, similar assays were carried out in 48-well (600 ml
total volume) plates to allow supernatant collection and analysis by
ELISAs. Transwell experiments were conducted in 96 well 0.4 mm
transwell plates (Corning, Lowell, MA) in 250 ml total volumes.
DCs were plated in the bottom chamber and stimulated
splenocytes in the top chamber. The 0.4 mm semi-permeable
membranes that separate the upper and lower chambers allow
diffusion of soluble materials but not cell migration. Control
conditions, consisting of wells containing only activated spleno-
cytes in the top chamber and media in the bottom chamber were
also performed.
RNA isolation and quantitative real-time PCR
RNA was purified from GM- or FL-DCs using TRIzol
according to the manufacturer’s instructions. Reverse transcription
was used to generate cDNA and qPCR was performed using
SYBR green. The primers used for qPCR analysis were the
following: b-actin forward, ACTAATGGCAACGAGCGGTTC
and reverse, GGATGCCACAGGATTCCATACC; Arg 1 for-
ward, CAGAAGAATGGAAGAGTCAG and reverse, CAGA-
TATGCAGGGAGTCACC; Arg 2 forward, ACAGGGTTGCT-
GTCAGCTCT and reverse, TGATCCAGACAGCCATTTCA;
Nos2 forward, CGAAACGCTTCACTTCCAA and reverse, TG-
AGCCTATATTGCTGTGGCT and Indo forward, AGAGCTC-
GCAGTAGGGAACAG and reverse, CATCACCATGGCGTA-
TGTG. Reactions were carried out in an ABI 7900 real-time PCR
machine (Applied Biosystems). Values are expressed relative to
actin.
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WT conventional T cells (CD4
+CD25
2CD45RB
hi)w e r e
cultured (RPMI 1640 supplemented with 10% FBS, 10 mM
HEPES, 2 mM glutamine, 1 mM sodium pyruvate, 1 mM
MEM non-essential amino acid solution, and 100 U/ml each of
penicillin G and streptomycin) in the presence of plate-bound
aCD3 (10 mg/ml, 2C11) and co-stimulated with SHIP+/+ or
2/2 DCs (2:1 ratio T cell to DC) in the presence of rhIL-2
(100 U/ml; Chiron). After 4 days, cells were harvested and
analyzed by flow cytometry for Treg induction based on
expression of CD4 (clone L3T4) and Foxp3 (clone FJK-16s)
(eBioscience).
Statistical analysis
Statistical significance was calculated using a two-tailed
unpaired student t test using Microsoft excel or GraphPad Prism.
Differences were considered significant when p,0.05.
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